Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...

Figure 1. Killing of tumor cells by CAR-NK cells. Specific binding of the chimeric antigen receptor to its target antigen on the tumor-cell surface triggers CAR activation. This results in ...

CAR-NK cell therapies and combinations of existing treatments also work to restore the innate killing capacity of NK cells in MM. Given the success of blocking T cell IRs in multiple cancer types, ...

1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost. Researchers at MD Anderson Cancer ...

and efficacy of CAR-T and CAR-Natural Killer (NK) cells. Its key features include: Bispecific Anti-CD19xCD22 CAR: This design targets both CD19 and CD22 antigens, minimizing the risk of tumor ...

NK cells are emerging as a potentially safer and more convenient alternative to the current generation of CAR-T cell therapies – which include Gilead/Kite's Yescarta (axicabtagene ciloleucel ...

Major Finding: HIV Nef expression reduces allorecognition and apoptotic cell death of CAR T cells. Concept: Controlled Nef expression reduces HLA-I levels and protects CAR T cells from CD8 + T cell– ...

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...